Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).

Peter Grell,Chia-Chi Lin,Michele Milella,Cheng Ean Chee,Shivan Sivakumar,Katriina Peltola,Geraldine Bostel,Dragana Jankovic,Maria-Athina Altzerinakou,Claire Fabre,Armando Santoro

Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).

2021

Peter Grell
Chia-Chi Lin
Michele Milella
Cheng Ean Chee
Shivan Sivakumar
Katriina Peltola
Geraldine Bostel
Dragana Jankovic
Maria-Athina Altzerinakou
Claire Fabre
Armando Santoro

TPS4173Background: Overall survival remains low for pts with mPDAC despite approved therapies, highlighting the need for further innovative treatment options. Intra-tumoral fibrosis that characteri...

Keywords:

in patient
Cancer research
Transforming growth factor
Monoclonal antibody
Medicine
pancreatic ductal adenocarcinoma
Fibrosis
Programmed cell death 1
Phases of clinical research
Gemcitabine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations